How Much Does Ambien (Zolpidem) Cost in Maryland in 2026?

Generic Zolpidem vs. Brand-Name Ambien: Maryland Pricing Breakdown

The single biggest factor affecting what you pay for zolpidem in Maryland is whether your pharmacy dispenses the generic or the brand. Brand-name Ambien, manufactured by Sanofi, carries a list price of roughly $120 per month for a 30-count supply of 10 mg tablets. Generic zolpidem tartrate, by contrast, averages about $15 per month across Maryland retail pharmacies in 2026.

That price gap exists because zolpidem lost patent exclusivity in 2007, and multiple manufacturers now produce FDA-rated bioequivalent generics 1. The FDA's Orange Book confirms therapeutic equivalence (an "AB" rating) between generic zolpidem tartrate immediate-release tablets and the Ambien reference listed drug. Maryland pharmacies are permitted to substitute generics automatically unless a prescriber writes "dispense as written" on the prescription.

Prices vary by pharmacy. Large chains like CVS, Walgreens, and Walmart in Maryland typically price generic zolpidem between $10 and $20 for a 30-day supply without insurance. Independent pharmacies may charge slightly more. Costco pharmacies in Maryland (you do not need a membership to use the pharmacy) have historically offered some of the lowest retail cash prices for generic medications in the state.

For the extended-release formulation (zolpidem ER, equivalent to Ambien CR), expect higher cash prices. Generic zolpidem ER typically runs $25 to $45 per month at Maryland pharmacies, depending on dose and retailer.

Maryland Medicaid Coverage for Zolpidem

Maryland Medicaid covers zolpidem, but a prior authorization requirement applies. This means your prescriber must submit clinical documentation to Maryland's Medicaid pharmacy program before the prescription will be approved for coverage.

The prior authorization process in Maryland typically requires the prescriber to document that the patient has a diagnosed insomnia disorder, has attempted non-pharmacologic interventions (such as cognitive behavioral therapy for insomnia, or CBT-I), and that zolpidem is clinically appropriate given the patient's medication history. The American Academy of Sleep Medicine's 2017 clinical practice guideline recommends CBT-I as first-line therapy for chronic insomnia in adults, with pharmacotherapy reserved for patients who do not respond adequately or who need short-term relief while behavioral treatment takes effect 2.

Maryland Medicaid managed care organizations (MCOs), including Priority Partners, Jai Medical Systems, and CareFirst Community Health Plan Maryland, each maintain their own preferred drug lists. Generic zolpidem immediate-release is generally the preferred agent within the sedative-hypnotic class. Brand-name Ambien and Ambien CR usually require step therapy through the generic first.

If prior authorization is approved, the copay for Maryland Medicaid enrollees is minimal. Most Medicaid recipients in Maryland pay $0 to $3 per prescription for preferred generics.

Insurance Coverage Beyond Medicaid

Most commercial insurance plans in Maryland cover generic zolpidem on their formularies. The drug sits on Tier 1 (preferred generic) for the majority of plans sold through the Maryland Health Benefit Exchange and employer-sponsored plans operating in the state.

Tier 1 copays in Maryland commercial plans typically range from $5 to $15 for a 30-day supply. Plans from CareFirst BlueCross BlueShield, Kaiser Permanente of the Mid-Atlantic States, Aetna, Cigna, and UnitedHealthcare all list generic zolpidem IR as a preferred generic. Brand-name Ambien, when requested with a "dispense as written" notation, usually falls on Tier 3 (non-preferred brand) with copays of $40 to $75.

Medicare Part D plans in Maryland follow a similar pattern. The 2026 Part D benefit structure, updated under the Inflation Reduction Act provisions that took effect in 2025, caps total annual out-of-pocket prescription spending at $2,000 3. For a low-cost generic like zolpidem, this cap is unlikely to be relevant on its own, but it provides meaningful protection for Medicare enrollees taking multiple medications.

One consideration specific to zolpidem: the FDA revised dosing recommendations in 2013, lowering the recommended dose for women to 5 mg for the immediate-release formulation due to pharmacokinetic data showing slower zolpidem clearance in women 4. Some insurers may flag a 10 mg prescription for a female patient for quantity or dose review. This is not a denial; it is a clinical edit that the prescriber can usually resolve with a brief note.

Compounded Zolpidem in Maryland: Legality and Access

Compounded zolpidem is legal in Maryland when prepared by a pharmacy operating under a valid 503A license. Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound medications based on individual patient prescriptions 5.

A 503A compounding pharmacy in Maryland can prepare zolpidem in alternative dosage forms (sublingual troches, liquid suspensions, custom-dose capsules) when a prescriber determines that a commercially available product does not meet the patient's clinical needs. Common reasons for compounding zolpidem include patients who cannot swallow tablets, patients who need a dose not commercially available, or patients with allergies to inactive ingredients in manufactured products.

Cost is another factor. Some 503A pharmacies in Maryland price compounded zolpidem competitively with, or below, the retail generic price. However, insurance coverage for compounded medications is inconsistent. Most commercial plans and Maryland Medicaid do not routinely cover compounded prescriptions unless the plan includes a compounding benefit or the prescriber obtains a prior authorization documenting medical necessity.

Patients considering compounded zolpidem should verify that the pharmacy holds both a valid Maryland Board of Pharmacy license and complies with USP 795 compounding standards. The Maryland Board of Pharmacy maintains a public license verification tool.

Telehealth Prescribing of Zolpidem in Maryland

Maryland permits telehealth prescribing of zolpidem. The state's telehealth parity law (Md. Code, Health-General § 15-105.2) requires insurers to cover telehealth services on par with in-person visits, provided the service is clinically appropriate.

There is one significant constraint. Zolpidem is a Schedule IV controlled substance under both federal and Maryland law. The DEA's post-pandemic telehealth prescribing framework, finalized in late 2025, allows initial prescriptions of Schedule III through V controlled substances via audio-video telehealth if the prescriber conducts a real-time, two-way audio-video evaluation and documents it in the medical record 6. Audio-only (phone-only) encounters are not sufficient for an initial controlled substance prescription under the current federal rule.

Maryland-based telehealth platforms and out-of-state platforms licensed in Maryland can prescribe zolpidem if the prescriber holds an active Maryland medical license and a valid DEA registration. The prescription must be transmitted electronically to a Maryland pharmacy via an EPCS (Electronic Prescribing for Controlled Substances) compliant system.

For patients with established prescriber relationships, telehealth refill visits for zolpidem are straightforward. Many Maryland health systems, including Johns Hopkins Medicine and the University of Maryland Medical System, offer telehealth follow-up visits for sleep medicine.

Savings Cards, Discount Programs, and Cost-Reduction Strategies

Several pathways can reduce zolpidem costs for Maryland residents. The most practical ones, ranked by likely savings:

Pharmacy discount cards. Programs like GoodRx, RxSaver, and SingleCare negotiate discounted cash prices with participating pharmacies. In Maryland, these programs frequently bring generic zolpidem IR below $10 for a 30-day supply. These cards are free and can be used by anyone, including insured patients whose copay exceeds the discount price.

Manufacturer savings programs. Sanofi has periodically offered savings cards for brand-name Ambien, though availability changes year to year. Generic zolpidem manufacturers do not typically offer direct-to-consumer savings cards because the retail price is already low.

Maryland Pharmacy Assistance Program. The state's Senior Prescription Drug Assistance Program (SPDAP) helps Maryland residents aged 65 and older (or those with disabilities) who have Medicare Part D. SPDAP can cover Part D premiums, deductibles, and copays, indirectly reducing zolpidem costs for qualifying enrollees.

Pill splitting (with prescriber approval). Zolpidem 10 mg tablets are scored and can be split. A prescriber can write for 10 mg tablets with instructions to take half a tablet at bedtime, effectively halving the per-dose cost. This approach is pharmacologically sound for the immediate-release formulation but must not be used with extended-release (zolpidem ER) tablets, which should never be split or crushed 4.

90-day supply pricing. Many Maryland pharmacies and mail-order services offer a lower per-unit price for 90-day fills. Express Scripts, CVS Caremark, and OptumRx mail-order pharmacies frequently price 90-day generic zolpidem at $20 to $30 total.

Clinical Context: What Zolpidem Does and Duration-of-Use Guidance

Zolpidem is a non-benzodiazepine sedative-hypnotic that acts on the GABA-A receptor's alpha-1 subunit. It reduces sleep latency (time to fall asleep) without substantially altering sleep architecture at recommended doses. In the Krystal et al. (2010) extended-use trial, zolpidem 10 mg maintained efficacy over 12 months in adults with chronic primary insomnia, with a mean reduction in subjective sleep latency of approximately 20 minutes compared to placebo 7.

Short-term use remains the standard recommendation. The American Academy of Sleep Medicine states: "We suggest that clinicians use zolpidem as a treatment for sleep onset insomnia in adults (versus no treatment)" while noting that the recommendation applies to short-term use, typically 4 to 5 weeks, with reassessment at regular intervals 2.

Dr. Andrew Krystal, Professor of Psychiatry and Behavioral Sciences at UCSF, has noted that "the clinical challenge with zolpidem is not efficacy but rather appropriate duration of use and ongoing monitoring for tolerance, rebound insomnia, and complex sleep behaviors" 7.

The FDA added a boxed warning to all zolpidem products in 2019 after post-marketing reports of serious injuries and deaths associated with complex sleep behaviors (sleepwalking, sleep-driving, engaging in activities while not fully awake) 8. The boxed warning states: "Complex sleep behaviors including sleepwalking, sleep driving, and engaging in other activities while not fully awake may occur following the first or any subsequent use of zolpidem, with or without the concomitant use of alcohol and other CNS depressants."

Patients filling zolpidem at Maryland pharmacies should expect to receive the FDA Medication Guide with each dispensing.

Maryland-Specific Regulatory Considerations

Maryland follows standard DEA scheduling for zolpidem (Schedule IV). The state does not impose additional scheduling restrictions beyond the federal classification. Maryland's Prescription Drug Monitoring Program (PDMP), known as CRISP (Chesapeake Regional Information System for our Patients), requires prescribers to check the PDMP before issuing a new controlled substance prescription 9.

Prescriptions for zolpidem in Maryland are valid for six months from the date written and may include up to five refills within that six-month period, consistent with federal Schedule IV dispensing rules. Electronic prescribing for controlled substances (EPCS) is the standard transmission method; Maryland adopted mandatory EPCS for controlled substances effective January 1, 2022.

Quantity limits may apply under insurance plans. Most Maryland Medicaid MCOs and commercial insurers limit zolpidem to 30 tablets per 30-day period, corresponding to one tablet nightly. Requests exceeding this quantity typically trigger a prior authorization review.

For Maryland residents who fill prescriptions at out-of-state pharmacies (common in border areas near Delaware, Pennsylvania, Virginia, and Washington, D.C.), the prescription remains valid as long as the prescriber holds an active license in the state where the patient encounter occurred and the dispensing pharmacy operates lawfully in its own state.

Head-to-Head: Zolpidem Pricing vs. Other Maryland Insomnia Medications

Zolpidem is not the only option. Comparing approximate 2026 Maryland cash prices for a 30-day supply of common insomnia medications:

Generic zolpidem IR 10 mg runs about $15. Eszopiclone (generic Lunesta) 3 mg costs approximately $20 to $30. Suvorexant (Belsomra) 20 mg, still brand-only, lists at around $400 per month. Lemborexant (Dayvigo) 10 mg, also brand-only, lists near $350 per month. Trazodone 50 mg (off-label for insomnia, generic) costs roughly $8 to $12 10.

Generic zolpidem remains one of the most affordable prescription insomnia treatments available in Maryland. Trazodone is cheaper but carries a different side-effect profile and is not FDA-approved for insomnia. The dual orexin receptor antagonists (suvorexant, lemborexant) offer a newer mechanism but at a substantially higher price point, and insurance coverage often requires step therapy through zolpidem or eszopiclone first.

The Sateia et al. (2017) clinical practice guideline from the AASM provides weak recommendations for both zolpidem and suvorexant, noting that the choice between agents should be individualized based on patient characteristics, comorbidities, and cost 2.

For a Maryland patient paying cash and prioritizing cost, generic zolpidem IR with a pharmacy discount card ($8 to $15) or trazodone ($8 to $12) will be the most affordable options at bedtime.